Impact of a low-oxygen environment on the efficacy of antimicrobials against intracellular Chlamydia trachomatis

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 5, 2011, Pages 2319-2324

  Shima, Kensuke ^a   Szaszák, Márta ^a   Solbach, Werner ^a   Gieffers, Jens ^b   Rupp, Jan ^a,c  

^a UNIVERSITY OF LÜBECK   (Germany)

^b DIAMEDIS   (Germany)

^c Medical Clinic III   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; DOXYCYCLINE; MOXIFLOXACIN; MULTIDRUG RESISTANCE PROTEIN 1; OXYGEN; RIFAMPICIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; CHLAMYDIA TRACHOMATIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; HOST CELL; HYPOXIA; INFLAMMATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OXYGEN CONCENTRATION; PRIORITY JOURNAL; UROGENITAL SYSTEM;

ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; AZITHROMYCIN; CELL HYPOXIA; CELL LINE; CHLAMYDIA TRACHOMATIS; DOXYCYCLINE; FEMALE; HUMANS; MICROBIAL SENSITIVITY TESTS; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; QUINOLINES; RIFAMPIN;

EID: 79955532740     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01655-10     Document Type: Article

References (38)

1. Batteiger, B. E., et al. 2010. Repeated Chlamydia trachomatis genital infections in adolescent women. J. Infect. Dis. 201:42-51.
2. Bosquillon, C. 2010. Drug transporters in the lung - do they play a role in the biopharmaceutics of inhaled drugs? J. Pharm. Sci. 99:2240-2255.
3. Bussmeyer, U., et al. 2010. Impairment of gamma interferon signaling in human neutrophils infected with Anaplasma phagocytophilum. Infect. Immun. 78:358-363.
4. Cattamanchi, A., et al. 2009. Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Clin. Infect. Dis. 48: 179-185.
5. Centers for Disease Control and Prevention. 2006. Sexually transmitted diseases treatment guidelines, 2006. MMWR Morb. Mortal. Wkly. Rep. 55(RR-11):1-94.
6. Centers for Disease Control and Prevention. 2009. Chlamydia screening among sexually active young female enrollees of health plans - United States, 2000-2007. MMWR Morb. Mortal. Wkly. Rep. 58:362-365.
7. Centers for Disease Control and Prevention. 2008. Sexually transmitted disease surveillance, 2007, p. 1-168. Centers for Disease Control and Prevention, Atlanta, GA.
8. Comerford, K. M., et al. 2002. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 62:3387-3394. (Pubitemid 34651384)
9. Cooper, M. A., K. Nye, J. M. Andrews, and R. Wise. 1990. The pharmacokinetics and inflammatory fluid penetration of orally administered azithromycin. J. Antimicrob. Chemother. 26:533-538.
10. Denny, W. A. 2000. The role of hypoxia-activated prodrugs in cancer therapy. Lancet Oncol. 1:25-29.
11. Eggert-Kruse, W., et al. 2002. Seminal antibodies to human 60kd heat shock protein (HSP 60) in male partners of subfertile couples. Hum. Reprod. 17:726-735.
12. Forrest, G. N., and K. Tamura. 2010. Rifampin combination therapy for nonmycobacterial infections. Clin. Microbiol. Rev. 23:14-34.
13. Gieffers, J., J. Rupp, A. Gebert, W. Solbach, and M. Klinger. 2004. First-choice antibiotics at subinhibitory concentrations induce persistence of Chlamydia pneumoniae. Antimicrob. Agents Chemother. 48:1402-1405.
14. Gillespie, S. H. 2002. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob. Agents Chemother. 46:267-274.
15. Grayo, S., O. Join-Lambert, M. C. Desroches, and M. A. Le. 2008. Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes. Antimicrob. Agents Chemother. 52:1697-1702.
16. Höckel, M., K. Schlenger, C. Knoop, and P. Vaupel. 1991. Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements. Cancer Res. 51:6098-6102.
17. Juul, N., H. Jensen, M. Hvid, G. Christiansen, and S. Birkelund. 2007. Characterization of in vitro chlamydial cultures in low-oxygen atmospheres. J. Bacteriol. 189:6723-6726. (Pubitemid 47397379)
18. Lenaerts, A. J., et al. 2007. Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Antimicrob. Agents Chemother. 51:3338-3345.
19. Leslie, E. M., R. G. Deeley, and S. P. Cole. 2005. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 204:216-237.
20. Michot, J. M., C. Seral, B. F. Van, M. P. Mingeot-Leclercq, and P. M. Tulkens. 2005. Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages. Antimicrob. Agents Chemother. 49:2429-2437.
21. Mpiga, P., and M. Ravaoarinoro. 2006. Chlamydia trachomatis persistence: an update. Microbiol. Res. 161:9-19.
22. Nichterlein, T., et al. 1998. Reduced intracellular activity of antibiotics against Listeria monocytogenes in multidrug resistant cells. Int. J. Antimicrob. Agents 10:119-125.
23. Paavonen, J., and W. Eggert-Kruse. 1999. Chlamydia trachomatis: impact on human reproduction. Hum. Reprod. Update 5:433-447.
24. Pruul, H., and P. J. McDonald. 1992. Potentiation of antibacterial activity of azithromycin and other macrolides by normal human serum. Antimicrob. Agents Chemother. 36:10-16.
25. Roth, A., et al. 2010. Hypoxia abrogates antichlamydial properties of IFN-gamma in human fallopian tube cells in vitro and ex vivo. Proc. Natl. Acad. Sci. U. S. A. 107:19502-19507.
26. Rupp, J., et al. 2007. Chlamydia pneumoniae directly interferes with HIF- 1alpha stabilization in human host cells. Cell Microbiol. 9:2181-2191. (Pubitemid 47250290)
27. Rupp, J., et al. 2005. Chlamydia pneumoniae infection promotes a proliferative phenotype in the vasculature through Egr-1 activation in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 102:3447-3452.
28. Rustad, T. R., A. M. Sherrid, K. J. Minch, and D. R. Sherman. 2009. Hypoxia: a window into Mycobacterium tuberculosis latency. Cell Microbiol. 11:1151-1159.
29. Semenza, G. L. 2010. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29:625-634.
30. Seral, C., et al. 2003. Influence of P-glycoprotein inhibitors on accumulation of macrolides in J774 murine macrophages. Antimicrob. Agents Chemother. 47:1047-1051.
31. Siewert, K., J. Rupp, M. Klinger, W. Solbach, and J. Gieffers. 2005. Growth cycle-dependent pharmacodynamics of antichlamydial drugs. Antimicrob. Agents Chemother. 49:1852-1856.
32. Sun, H., and P. He. 2009. Characterization of interaction between doxycycline and human serum albumin by capillary electrophoresis-frontal analysis. Electrophoresis 30:1991-1997.
33. Tulkens, P. M. 1991. Intracellular distribution and activity of antibiotics. Eur. J. Clin. Microbiol. Infect. Dis. 10:100-106.
34. Vaupel, P., M. Hockel, and A. Mayer. 2007. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid. Redox. Signal. 9:1221-1235.
35. Walter, S., J. Kuchenbecker, P. Banditt, S. M. Bode-Boger, and W. Behrens- Baumann. 2007. Concentration of moxifloxacin in serum and human aqueous humor following a single 400 mg oral dose. J. Cataract Refract. Surg. 33:553-555.
36. WHO. 2001. Global prevalence and incidence of selected curable sexually transmitted diseases: overview and estimates, p. 1-43. World Health Organization Department of HIV/AIDS, Geneva, Switzerland.
37. Zalcberg, J., et al. 2000. MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines. Prostate Cancer Prostatic Dis. 3:66-75. (Pubitemid 30663591)
38. Zeitlinger, M., et al. 2008. Plasma protein binding of fluoroquinolones affects antimicrobial activity. J. Antimicrob. Chemother. 61:561-567.